| Literature DB >> 35928932 |
Keyan Zhao1, Baoyin Li1, Biao Sun1, Dengshun Tao1, Hui Jiang1, Huishan Wang1.
Abstract
Objective: To analyze the survival and risk factors associated with the surgical treatment of ventricular septal rupture (VSR) after acute myocardial infarction (AMI).Entities:
Keywords: acute myocardial infarction; risk factor; surgery; survival; ventricular septal rupture
Year: 2022 PMID: 35928932 PMCID: PMC9345494 DOI: 10.3389/fcvm.2022.933103
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Patient characteristics.
|
|
| |||
|---|---|---|---|---|
| Age (years) | 63.58 ± 8.21 | 63.36 ± 8.18 | 64.44 ± 8.79 | 0.7278 |
| Male (%) | 25 (55.56%) | 19 (52.78%) | 6 (66.67%) | 0.7095 |
| Weight (kg) | 65.72 ± 9.37 | 65.48 ± 9.15 | 66.67 ± 10.75 | 0.7385 |
| Diabetes mellitus, | 14 (31.11%) | 10 (27.78%) | 4 (44.44%) | 0.4275 |
| Previous infarction, | 1 (2.22%) | 1 (2.78%) | 0 (0.00%) | 1 |
| History of PCI, | 13 (28.89%) | 10 (27.78%) | 3 (33.33%) | 0.7037 |
| History of smoking, | 18 (40.00%) | 1 3 (36.11%) | 5 (55.56%) | 0.4487 |
|
| 0.1863 | |||
| 1 | 1 (2.22%) | 0 (0.00%) | 1 (11.11%) | |
| 2 | 8 (17.78%) | 7 (19.44%) | 1 (11.11%) | |
| 3 | 9 (20.00%) | 8 (22.22%) | 1 (11.11%) | |
| 4 | 27 (60.00%) | 21 (58.33%) | 6 (66.67%) | |
|
| 0.2404 | |||
| Single vessel disease, | 22 (48.89%) | 19 (52.78%) | 3 (33.33%) | |
| Double vessel disease, | 16 (35.56%) | 13 (36.11%) | 3 (33.33%) | |
| Triple vessel disease, | 7 (15.56%) | 4 (11.11%) | 3 (33.33%) | |
|
| ||||
| LVEF | 0.46 ± 0.07 | 0.46 ± 0.07 | 0.46 ± 0.10 | 0.9378 |
| LVESD (mm) | 37.63 ± 4.80 | 37.55 ± 5.00 | 38.00 ± 4.04 | 0.8234 |
| LVEDD (mm) | 48.65 ± 4.51 | 48.53 ± 3.77 | 49.11 ± 6.92 | 0.8134 |
| Left atria diameter (mm) | 38.98 ± 5.17 | 39.35 ± 5.18 | 37.56 ± 5.17 | 0.36 |
| Serum creatinine (μmol/L) | 91.55 ± 36.84 | 82.61 ± 27.80 | 127.32 ± 47.82 | 0.0238 |
| NT-proBNP (pg/mL) | 5,153.00 (2,165.74–9,587.50) | 4,268.96 (1,800.00–7,894.00) | 8,654.00 (6,197.00–11,949.00) | 0.0134 |
| Hemoglobin level (g/L) | 116.07 ± 12.17 | 117.56 ± 10.55 | 110.11 ± 16.65 | 0.101 |
| Time from AMI to VSR (days) | 3.00 (2.00–6.00) | 3.00 (2.00–4.00) | 6.00 (3.00–7.00) | 0.1867 |
| Time from VSR to surgery (days) | 21.00(14.00–28.00) | 21.00(16.00–28.00) | 23.00(13.00–27.00) | 0.6085 |
| Time from VSR to surgery | 0.2188 | |||
| ≤ 14 days, | 12(26.67%) | 8(22.22%) | 4(44.44%) | |
| >14 days, | 33(73.33%) | 28(77.78%) | 5(55.56%) | |
| Pulmonary systolic pressure (mmHg) | 61.24 ± 12.82 | 62.25 ± 13.05 | 57.22 ± 11.66 | 0.2978 |
| CPB time (min) | 121.00 (107.00–156.00) | 119.00 (103.00–151.50) | 131.00 (121.00–184.00) | 0.0454 |
| Aortic cross time (min) | 69.00 (55.00–89.00) | 64.00 (54.50–89.00) | 78.00 (69.00–90.00) | 0.2276 |
| IABP implantation, | 27 (64.29%) | 18 (54.55%) | 9 (100.00%) | 0.016 |
| ECMO, | 2 (100.00%) | 0 (0.00%) | 2 (100.00%) | - |
| Ventilation time (h) | 44.50 (39.50–92.00) | 44.00 (25.50–70.00) | 134.50 (62.00–216.00) | 0.0022 |
| Residual shunt, | 7 (15.91%) | 4 (11.11%) | 3 (33.33%) | 0.1307 |
|
| 0.038 | |||
| None, | 38 (84.44%) | 32 (88.89%) | 6 (66.67%) | |
| Mild, | 5 (11.11%) | 4 (11.11%) | 1 (11.11%) | |
| Moderate, | 1 (2.22%) | 0 (0.00%) | 1 (11.11%) | |
| Severe, | 1 (2.22%) | 0 (0.00%) | 1 (11.11%) | |
|
| 1 | |||
| Anterior, | 38 (84.44%) | 30 (83.33%) | 8 (88.89%) | |
| Posterior, | 7 (15.56%) | 6 (16.67%) | 1 (11.11%) | |
| Diameter (cm) | 1.79 ± 0.57 | 1.74 ± 0.52 | 2.01 ± 0.70 | 0.195 |
| Transfusion of RBC (units) | 4.00 (1.50–8.50) | 3.75 (0.00–7.00) | 11.60 (6.10–16.50) | 0.0025 |
| Use of LIMA, | 10 (22.22%) | 9 (25.00%) | 1 (11.11%) | 0.659 |
|
| 0.4038 | |||
| 0, | 4 (8.89%) | 3 (8.33%) | 1 (11.11%) | |
| 1, | 27 (60.00%) | 23 (63.89%) | 4 (44.44%) | |
| 2, | 10 (22.22%) | 6 (16.67%) | 4 (44.44%) | |
| 3, | 3 (6.67%) | 3 (8.33%) | 0 (0.00%) | |
| 4, | 1 (2.22%) | 1 (2.78%) | 0 (0.00%) |
Data are presented as mean ± standard deviation, mean (range), or number (%).
AMI, acute myocardial infarction; IABP, intra-aortic balloon pump; CPB, cardiopulmonary bypass; ECMO, extracorporeal membrane oxygenation; LIMA, left internal mammary artery; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; RBC, red blood cell; VSR, ventricular septal rupture. P values in bold are considered significantly different (P <0.05).
Figure 1All-cause mortality during follow-up. (A) The Kaplan–Meier survival curve. (B) The time between ventricular septal rupture (VSR) and repair was not associated with all-cause mortality at ≤ 14 days and >14 days (33.33 vs. 15.15%; log-rank P = 0.10). However, the 1-month landmark analysis showed that compared to patients with VSR to surgical time > 14 days, those who underwent surgery within 14 days had a higher rate of all-cause mortality (25.00 vs. 3.33%; log-rank P = 0.023).
Independent risk factors for mortality.
|
|
|
|
|---|---|---|
|
| ||
| Increase of NT-proBNP per 100 pg/mL | 1.019 (1.001–1.037) | 0.035 |
| Transfusion of RBC per 1 unit | 1.328 (1.096–1.610) | 0.0038 |
|
| ||
| Transfusion of RBC per 1 unit | 1.189 (1.010–1.399) | 0.0373 |
|
| ||
| Transfusion of RBC per 1 unit | 1.238 (1.028–1.491) | 0.0243 |
|
| ||
| Increase of NT-proBNP per 100 pg/mL | 1.017 (1.001–1.033) | 0.0373 |
| Transfusion of RBC per 1 unit | 1.466 (1.144–1.879) | 0.0025 |
MACCE, major adverse cardiovascular and cerebrovascular events; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RBC, red blood cells; OR, odds ratio; CI, confidence interval.